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Over the past decade, pharmacologic coronary artery vaso-
dilation in combination with single-photon emission com-
puted tomography (SPECT) myocardial perfusion imaging
has become an increasingly popular approach to the nonin-
vasive detection of coronary artery disease. Numerous stud-
ies document comparable diagnostic accuracy of myocardial
perfusion imaging with dynamic exercise and with pharma-
cologic coronary artery vasodilation (1). Single-photon
emission computed tomography imaging after either dipy-
ridamole or adenosine infusion has provided a valuable
diagnostic tool in patients who are unable to exercise to
target heart rate. In addition, pharmacologic coronary artery
vasodilation should be substituted for dynamic exercise in
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the detection of coronary artery disease by SPECT imaging
in patients with left bundle branch block or an implanted
electronic pacemaker. In these patients, exercise-induced
tachycardia can result in SPECT defects in the absence of
coronary artery stenosis. At times pharmacologic stress has
been substituted for dynamic exercise in patients receiving
beta-adrenergic blockers because a beta-blocker might pre-
vent the patient from reaching the target heart rate with
exercise and interfere with the induction of myocardial
ischemia (2). However, Sharir et al. (3) have cautioned that
the continuation of antianginal drugs at the time of dipy-
ridamole SPECT myocardial imaging could substantially
reduce diagnostic sensitivity for the detection of single vessel
coronary disease.
The current report by Taillefer et al. (4) in this issue of
the Journal focuses specifically on the impact of beta-
blockers on the diagnostic sensitivity of SPECT myocardial
perfusion imaging with dipyridamole infusion. The authors
completed a prospective, double-blind study of 21 patients
with catheterization-proven coronary artery disease. The
patients were randomly assigned to dipyridamole perfusion
imaging on separate days with placebo, low-dose metoprolol
(up to 10 mg intravenously), or high-dose metoprolol (up to
20 mg intravenously). By qualitative interpretation, the
sensitivity of dipyridamole perfusion imaging for detection
of individual coronary artery stenoses was 69% with placebo
versus 52% with either low-dose or high-dose metoprolol (p
 0.039). The quantitative summed stress score was larger
after placebo (11.5  10.4) than low-dose (8.4  9.2) or
high-dose (9.1  10.8) metoprolol (both p  0.005). The
authors conclude that the presence and severity of ischemic
coronary artery disease may be underestimated in patients
receiving beta-blocker therapy while undergoing dipyridam-
ole stress myocardial perfusion imaging.
What is the mechanism by which a beta-blocker might
interfere with the production of perfusion defects in
response to dipyridamole infusion? One theoretic possi-
bility is that the beta-blocker could prevent an increase in
myocardial oxygen demand by preventing the modest reflex
tachycardia that often occurs with dipyridamole infusion.
Although heart rate did increase significantly in placebo-
treated patients with dipyridamole infusion in the Taillefer
et al. (4) study, systolic and diastolic blood pressure fell
significantly so that the rate-pressure product remained
unchanged. This suggests that dipyridamole infusion did
not produce perfusion defects under placebo conditions by
increasing myocardial oxygen consumption and inducing
ischemia.
The activation of beta-adrenergic receptors by cat-
echolamines induces coronary artery vasodilation, increasing
myocardial oxygen supply. Under baseline conditions, beta-
blockade produces coronary artery vasoconstriction (5),
possibly by leaving alpha-adrenergic activity unopposed.
Under conditions of dipyridamole-induced coronary artery
vasodilation, however, it has been demonstrated that meto-
prolol results in a reduction in coronary vascular resistance
and an increase in coronary blood flow (6,7). Because a
beta1-blocker would not directly dilate coronary arteries, it is
likely that the observed reduction in coronary vascular
resistance and increase in coronary blood flow is an indirect
result of negative inotropic, negative chronotropic and,
possibly, anti-ischemic effects.
Beller et al. (8) showed that in a setting of severe
single-vessel coronary artery stenosis, dipyridamole infusion
induces the coronary steal phenomenon by reducing post-
stenotic subendocardial blood flow while maintaining or
increasing post-stenotic subepicardial flow. In contrast,
metoprolol can increase subendocardial blood flow to the
post-stenotic myocardium in the presence of dipyridamole,
resulting in improved regional wall thickening (5). This may
result from reduced myocardial compression of intramyo-
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cardial subendocardial vessels through the negative inotro-
pic effect of the beta-blocker. Beta-blockers may also help
maintain intramyocardial coronary collateral flow by a
similar mechanism, and this may avert the coronary steal
phenomenon otherwise induced by dipyridamole. Addition-
ally, beta-blockers may reduce ischemia by slowing the heart
rate, thereby facilitating diastolic coronary flow.
Indirect support for the postulate that beta-blockade
ameliorates maldistribution of blood flow induced by dipy-
ridamole infusion comes from a dipyridamole echocardio-
graphic study reported by Lattanzi et al. (9). Patients were
tested with and without antianginal drugs, including pro-
pranolol in 27 patients. The sensitivity of dipyridamole
echocardiography fell from 91% off antianginal therapy to
65% on therapy (p 0.01). Dipyridamole echocardiography
depends upon maldistribution of myocardial blood flow
away from the subendocardium to induce regional wall
motion abnormality, an effect that was prevented by anti-
anginal treatment. It appears that beta-blockers, by averting
this maldistribution of myocardial blood flow, can prevent
detection of coronary artery stenosis during pharmacologic
myocardial perfusion imaging with dipyridamole.
What are the limitations of the Taillefer et al. (4)
study? The study is small—21 patients completed the study
protocol. This may well have prevented the identification of
a statistically significant effect of beta-blockade on per-
patient sensitivity for the detection of coronary disease with
dipyridamole infusion. Study size did not prevent statisti-
cally significant reductions in quantitative perfusion defect
size with metoprolol. Study design did not include patients
in whom coronary disease was absent; therefore, the effects
of beta-blockers on test specificity, normalcy rate, and
overall accuracy are unclear. The study was performed with
acute intravenous rather than chronic oral beta-blocker
administration and thereby differs from the usual clinical
scenario encountered in patients presenting for dipyridam-
ole myocardial perfusion imaging. Furthermore, the results
obtained with the beta1-selective blocker, metoprolol, may
not be the same for treatment with nonselective beta-
blockers, such as propranolol or carvedilol.
What then are the clinical implications of the findings
reported by Taillefer et al. (4)? Several studies have
suggested that antianginal drugs interfere with detection of
coronary artery disease with pharmacologic coronary artery
vasodilation (3,10). Taillefer et al. (4) now present data
focusing specifically on the interference of metoprolol with
detection of coronary disease with dipyridamole myocardial
perfusion testing. In patients referred for dipyridamole
myocardial perfusion imaging for the purpose of determin-
ing the presence or extent of coronary disease, strong
consideration should be given to withholding beta-blockers
for four to five half-lives (e.g., 36 to 48 h) before testing.
When the purpose of testing is to assess the clinical
effectiveness of antianginal treatment, the beta-blocker
should be continued. The decision to withhold beta-
blockers for diagnostic testing must be considered carefully
for each individual patient. Although small, there is a finite
risk of life-threatening complications, including severe hy-
pertension or an unstable coronary syndrome with beta-
blocker withdrawal (11–14). Therefore, withholding beta-
blockers for diagnostic testing may not be appropriate in
high-risk patients. When beta-blockers are withheld for 36
to 48 h before diagnostic testing, the patient should be
advised of the importance of promptly seeking medical care
if symptoms of ischemia appear or escalate. New clinical
studies are needed to determine more precisely the duration
that beta-blockers, and other antianginal drugs should be
withheld to avoid compromising the sensitivity of myocar-
dial perfusion imaging with pharmacologic stress. Finally,
because dipyridamole acts by preventing the inactivation of
adenosine by adenosine deaminase and by preventing aden-
osine reuptake (15), it is likely that beta-blockers will
interfere with detection of coronary disease with adenosine
as well as with dipyridamole perfusion imaging. Further
studies will be needed to confirm the effects of beta-blockers
on dipyridamole perfusion imaging and to determine
whether the sensitivity of adenosine perfusion imaging is
compromised similarly.
In conclusion, the new data presented by Taillefer et al.
(4) suggest that beta-blockers should be withheld tempo-
rarily before dipyridamole infusion for detection of coronary
artery disease by myocardial perfusion imaging. The deci-
sion to withhold beta-blockers for diagnostic testing should
be carefully considered on a case-by-case basis.
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